| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
PEGs
PROTAC Linkers. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a linker molecule, Propargyl-PEG2-NHS ester itself has no intrinsic biological activity; it serves as a structural connector in the synthesis of PROTACs and other bioconjugates. The NHS ester reacts rapidly with primary amines (e.g., on a protein or ligand) under mild conditions, while the alkyne can be used for subsequent click chemistry. |
| ln Vivo |
No specific in vivo activity has been reported for this linker alone; its activity is derived from the final PROTAC molecule after conjugation with appropriate ligands. The in vivo efficacy of a complete PROTAC is determined in animal models.
|
| Enzyme Assay |
N/A; this compound is not assessed in enzyme/receptor binding assays. Its quality is typically confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥98% and a molecular weight of 269.25.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. In a standard bioconjugation protocol, the NHS ester is reacted with a primary amine-containing ligand in a buffer such as PBS (pH 7.4) at room temperature for 1-2 hours. The resulting alkyne-functionalized ligand can then be conjugated to an azide via CuAAC.
|
| Animal Protocol |
N/A; no animal studies are performed with the linker alone. For a final PROTAC conjugate, in vivo studies are conducted following institutional guidelines. The compound is typically formulated in a vehicle containing DMSO, PEG300, Tween-80, and saline and administered via oral gavage, IP, or IV injection.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 269.25, a molecular formula of C12H15NO6, and is a solid. It is typically stored at -20degC for up to 3 years in powder form or at -80degC for 6 months in a solvent. It is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human therapeutic or clinical applications. Standard chemical safety precautions should be observed during handling. The NHS ester is moisture-sensitive and should be handled in a dry environment.
|
| References | |
| Additional Infomation |
The PEG2 spacer enhances water solubility and reduces steric hindrance. This linker is widely used in bioconjugation, surface modification, and the synthesis of multifunctional biomolecules for drug delivery, diagnostics, and chemical biology applications. It enables a two-step "tag-and-modify" strategy, first conjugating to an amine, then to an azide.
|
| Molecular Formula |
C12H15NO6
|
|---|---|
| Molecular Weight |
269.250603914261
|
| Exact Mass |
269.089
|
| CAS # |
2512228-06-5
|
| PubChem CID |
88878524
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
19
|
| Complexity |
380
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C#CCOCCOCCC(=O)ON1C(=O)CCC1=O
|
| InChi Key |
DPJWFTQBPPRKGG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H15NO6/c1-2-6-17-8-9-18-7-5-12(16)19-13-10(14)3-4-11(13)15/h1H,3-9H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-(2-prop-2-ynoxyethoxy)propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~250 mg/mL (~928.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7140 mL | 18.5701 mL | 37.1402 mL | |
| 5 mM | 0.7428 mL | 3.7140 mL | 7.4280 mL | |
| 10 mM | 0.3714 mL | 1.8570 mL | 3.7140 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
